Scroll up
Top
Hand with scissors cutting a wire on the ASCVD timerHeart with a timer attached to it reading ASCVD

Defusing

ASCVD risk

Each day >2500 US adults die from cardiovascular disease (CVD),1 despite available therapies. Atherosclerotic cardiovascular disease (ASCVD) remains a threat to public health.2
DISCOVER MORE

It’s time to expect more

As the science of lipid management evolves, NewAmsterdam Pharma is dedicated to developing innovative therapies focused on low-density lipoprotein cholesterol (LDL-C) and beyond—designed to expand treatment options and address residual ASCVD risk.

Lipid evolution: From statins to “what’s next?”

A timeline in lipid managementA timeline in lipid management
Despite the availability of therapies for decades, millions of patients still fail to reach LDL-C goals. Even among those who do, residual ASCVD risk may remain.4,10

LDL-C Goals, Guidelines &
Treatment

EXPLORE

LDL-C & Beyond: Key Lipid Biomarkers in ASCVD

FIND OUT MORE

LLT Considerations 

& Tolerability

SEE DATA

Register to receive updates from NewAmsterdam Pharma

Contact us

References: 1. Tsao CW, Aday AW, Almarzooq ZI, et al; Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. doi:10.1161/CIR.0000000000001123 2. Makover ME, Shapiro MD, Toth PP. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness. Am J Prev Cardiol. 2022;12:100371. doi:10.1016/j.ajpc.2022.100371 3. Strandberg TE, Kovanen PT, Lloyd-Jones DM, Raal FJ, Santos RD, Watts GF. Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2024;404(10441):2462-2475. doi:10.1016/S0140-6736(24)02089-0 4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389. doi:10.1016/S0140-6736(94)90566-5 5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. American Chemical Society. Lovastatin. Molecule of the Week Archive. Published February 9, 2009. Accessed September 5, 2025. https://www.acs.org/molecule-of-the week/archive/l/lovastatin.html 7. ZETIA (ezetimibe) [prescribing information]. Organon & Co.; revised July 2023. Accessed September 5, 2025. Available from: https://www.fda.gov/drugsatfda 8. Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. Am Heart J. 2014;167(5):683-689. doi:10.1016/j.ahj.2014.01.014 9. Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: current status, controversies, and future directions. Trends Cardiovasc Med. 2020;30(3):179-185. doi:10.1016/j.tcm.2019.05.007 10. Reijnders E, van der Laarse A, Jukema JW, Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for predictive, preventive, personalized, participatory, and psycho-cognitive medicine. Front Cardiovasc Med. 2023;10:1264319. doi:10.3389/fcvm.2023.1264319